Kos Pharmaceuticals, Inc. - -- l--Niaspan.com - -- l--Advicor.com - -- l--Under Development - -- l--Home About Kos -|- Business Development & Licensing -|- Investor Relations -|- Products -|- Career Opportunities - Newsroom -|- Contacts - Kos Product Portfolio Kos has emerged as a significant player in cardiovascular therapeutics for patients with heart disease, still the number one killer in America.
Statins for high cholesterol - [Medication] - Quest Diagnostics Patient Health Library Statins for high cholesterol Examples Brand Name Chemical Name Mevacor lovastatin Altocor extended-release lovastatin Pravachol pravastatin Zocor simvastatin Lescol, Lescol XL fluvastatin Lipitor, Caduet [also contains amlodipine, a calcium channel blocker] atorvastatin Crestor rosuvastatin Vytorin ezetimibe and simvastatin Advicor extended-release niacin and ...
Nicotinic acid for high cholesterol - [Medication] - Quest Diagnostics Patient Health Library Nicotinic acid for high cholesterol Examples Immediate-release form Brand Name Chemical Name Niacor, Nicolar nicotinic acid or niacin Sustained-release form Brand Name Chemical Name Slo-Niacin nicotinic acid or niacin Extended-release form Brand Name Chemical Name Niaspan nicotinic acid or niacin Advicor niacin with lovastatin How It Works...
Advances in the Treatment of Cardiovascular Diseases - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
author: BioPortfolio - Knowledge Management, Market Analysis and Market Research
Advances in the Treatment of Cardiovascular Diseases - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
author: BioPortfolio - Knowledge Management, Market Analysis and Market Research
BTECH REGULATORY RADAR - Tracking the Movement of Key Products Through Clinical Trials - - - - BioNews BioWeb Companies Products BioReports - - - - - - BTECH REGULATORY RADAR - Tracking the Movement of Key Products Through Clinical Trials FDA APPROVED Kos Pharmaceuticals' (NASDAQ: KOSP) Advicor, which combines the active cholesterol-lowering ingredient of Merck's (NYSE: MRK) Mevacor (lovastatin) and the nutrient niacin, was approved by the FDA.
BTECH REGULATORY RADAR - Tracking the Movement of Key Products Through Clinical Trials (2/4/02) - - - - BioNews BioWeb Companies Products BioReports - - - - - - BTECH REGULATORY RADAR - Tracking the Movement of Key Products Through Clinical Trials (2/4/02) LAUNCHED IN THE U.S.Advicor (extended-release niacin/lovastatin) Advicor is a fixed-dose combination of lovastatin and Kos's niacin formulation, Niaspan.Advicor is...
Results From The American College of Cardiology Meeting - - - - BioNews BioWeb Companies Products BioReports - - - - - Results From The American College of Cardiology Meeting The 51st Annual Scientific Session of the American College of Cardiology concluded today in Atlanta, Georgia.Advicor generated an impressive magnitude of treatment effect in managing a broad spectrum of cholesterol-based abnormalities...
BioPortfolio Limited 247 Prescribing of Advicor versus two separate pills in the US 248 Statin + bile acid sequestrant combination 249 Colesevelam is better tolerated than older bile acid sequestrants 250 Statin + fish oil derivative combination 252 Statin + ezetimibe combination 254 Clinical trial data for simvastatin-ezetimibe combination 255 Ezetimibe combined with atorvastatin, lovastatin ...
BioPortfolio Limited 155 Drug overview 156 Clinical trial data 156 Lescol: 12-month event screen 159 Lescol strategic analysis 165 Lescol forecasts to 2011 166 Mevacor (lovastatin) – increasing erosion from genericization 169 Drug overview 170 Clinical trial data 170 Mevacor: 12-month event screen 173 Mevacor strategic analysis 175 Mevacor forecasts to 2011 178 Advicor (lovastatin/ER ...
Drug Approvals - A This newly approved or tentatively approved drug listing is an interim page intended to provide timely information on new drug products as a more comprehensive page is developedAdvicor (Niacin Extended Release & Lovastatin) Tablets, Rx Kos Pharmaceuticals, IncAdvicor (Niacin & Lovastatin) Tablets, Rx Kos...
http://www.fda.gov/cder/orange/appendix_a.txt 3, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN ACETAMINOPHEN, ACETAMINOPHEN (OTC) ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC) ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, ACETAMINOPHEN ACETAMINOPHEN, BUTALBITAL AND CAFFEINE, ACETAMINOPHEN ACETAMINOPHEN,...
../2001/21-249_Advicor_ Food and Drug Administration • Center for Drug Evaluation and Research Title Search Advicor (Niacin Extended-Release & Lovastatin) Tablets Company:--Kos Pharmaceuticals, Inc
author: USERNAME
C:\Data\Advicor-N21249\AP.SLR001.doc page 1
author: Valerie Jimenez
NDA Approvals for Calendar Year 2001 Braun 5 S 21-Feb-01 21-235 Prozac Weekly Fluoxetine Hydrochloride Eli Lilly 3 S 26-Feb-01 21-169 Reminyl Galantamine Hydrobromide Janssen Research 1 S 28-Feb-01 21-082 Tavist Allergy/Sinus/Headache Acetaminophen/Clemastine Fumarate/Pseudoephedrine Hydrochloride Novartis 4 S 01-Mar-01 21-257 Travatan Travoprost Alcon 1 P 16-Mar-01 21-262 Alphagan P Brimonidine Tartrate Allergan 3 S 16...
author: Brenda Harmon
Prescription and OTC Drug Product List 12/2001 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE CAPSULE; ORAL SYNALGOS-DC-A -A- @ WOMEN FIRST HLTHCARE 356.4MG;30MG;16MG N89166 001 MAY 14, 1986 DEC CAHN -D- @ WYETH AYERST 356.4MG;30MG;16MG N89166 001 MAY 14, 1986 DEC CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET; ORAL ANEXSIA 5/325 -D- AA MALLINCKRODT 325MG;5MG N40409...
KOS PHARMACEUTICALS These risks and uncertainties include regulatory risks associated with new drug applications for approval, the market acceptance of Advicor ™ and Niaspan® in Europe, the validity, scope and enforceability of any patents covering the Advicor ™ and Niaspan® products in the territory subject to the agreement, the effect of conditions in the pharmaceutical...
Btech Weekly Advicor combines the active cholesterol- lowering ingredient of Merck's (NYSE: MRK) Mevacor (lovastatin) and the vitamin niacin, and was approved by the FDA in mid- DecemberAdvicor is directed against the "bad" LDL cholesterol, whereas the niacin portion tends to raise "good" HDL cholesterolADVICOR BEATS PLAIN OLD...
author: Leon Henderson
subject: Coated Stents
Btech Weekly page 7
author: Leon Henderson
subject: Coated Stents
Embargoed for Release: 4 pm (ET) Sunday, July 21, 2002 Additionally, increased awareness of managing all lipid parameters bodes well for Kos' other cardiovascular product, Advicor TM (niacin extended- release/ lovastatin tablets), in gaining government formulary statusAdvicor has been added to formulary on health care plans representing over 200 million lives in the United...
author: Steve Sabicer
Embargoed for Release: 4 pm (ET) Sunday, July 21, 2002 page 2
author: Steve Sabicer
Kos: Kos is committed to being a leading provider of specialty pharmaceuticals.
FOR IMMEDIATE RELEASE The initial Advicor filing is being made in the United Kingdom , and Kos expects to receive marketing clearance there by mid-2003, followed by subsequent clearance in major European Union (EU) markets under the Mutual Recognition Procedure.Advicor in the United States has exceeded our expectations, and the success of Advicor has not come at...
Embargoed for Release: 4 pm (ET) Sunday, July 21, 2002 Constance Bienfait Executive Director Corporate Communications (305) 523-3658 - “ADVENT” STUDY HIGHLIGHTS SAFETY AND EFFICACY OF NIASPAN a IN DIABETIC PATIENTS - Kos Pharmaceuticals Files sNDA for Niaspan to Treat Diabetic Dyslipidemia - MIAMI , FL , July 22, 2002 – According to a study published today in the Archives of Internal Medicine, Niaspan a (extended-release ...
Kos Pharmaceuticals, Inc. - -- l--Overview - -- l--Management - -- l--Board of Directors - -- l--Future Objectives - -- l--Home About Kos -|- Business Development & Licensing -|- Investor Relations -|- Products -|- Career Opportunities - Newsroom -|- Contacts - Company Overview - Kos Pharmaceuticals, Inc.
